A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency

Summary

This study is a multi-center, open-label safety study assessing long-term somavaratan administration.

Timeline

Start

2017-03-31

Primary completion

2017-11-30

Completion

2017-11-30

Outcome

Outcome not reported

Stopped: “The primary endpoint of non-inferiority to daily therapy in the pediatric Phase 3 study was not achieved”

Drugs

Indications